2. Search Result
Search Result
Results for "

alpha+blocker

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P11097
    Pep-20

    		CD47 Cancer
    Pep-20 is a CD47/SIRPα blocking peptide with KD values of 2.91 and 3.63 μM for human and mouse CD47, respectively. IC50 values for blocking the human and mouse CD47/SIRPα interaction are 24.56 and 12.03 μM, respectively. Pep-20 has antitumor activity .
    Pep-20
  • HY-171878
    BI-4659

    		TGF-β Receptor PDGFR TGF-beta/Smad Inflammation/Immunology Cancer
    BI-4659 is a TGFβRI and PDGFRα inhibitor with IC50 values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and PDGFRα, blocks the downstream TGFβRI signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1. BI-4659 is applicable to research related to pulmonary fibrosis, cancer, and renal ischemia-reperfusion injury .
    BI-4659
  • HY-156596A
    Aneratrigine hydrochloride

    		Sodium Channel Neurological Disease
    Aneratrigine (hydrochloride) is a sodium channel protein type 9 subunit alpha blocker. Aneratrigine (hydrochloride) can be used for neuropathic pain diseases research .
    Aneratrigine hydrochloride
  • HY-168644
    Erα-IN-1

    		Estrogen Receptor/ERR Endocrinology
    Erα-IN-1 (compound 3c) is an inhibitor of estrogen receptor α (ERα), blocking ERa activity in MCF7/ERE-LUC cells. .
    Erα-IN-1
  • HY-181836
    IKKβ-IN-6

    		IKK Topoisomerase Apoptosis NF-κB Reactive Oxygen Species (ROS) Bcl-2 Family Cancer
    IKKβ-IN-6 is an antitumor agent. IKKβ-IN-6 inhibits IKKβ (IC50: 18.24 μM), thereby suppressing the phosphorylation of p65 and IκBα, blocking the nuclear translocation of p65, and subsequently regulating genes controlled by NF-κB. IKKβ-IN-6 also targets topoisomerase I (Topo I), induces DNA damage, ROS accumulation, loss of mitochondrial membrane potential, and S-phase arrest. IKKβ-IN-6 is applicable to related research on colorectal cancer .
    IKKβ-IN-6
  • HY-183741
    VVD-844

    		PI3K Akt Cancer
    VVD-844 is an orally active covalent inhibitor of PI3Kα inhibitor. VVD-844 covalently binds to Cys 242 in the RAS binding domain of p110α, blocking RAS-p110α interaction and inhibiting PI3Kα activity. VVD-844 inhibits PI3Kα signaling activation in HER2-overexpressing cells via a RAS-independent mechanism. VVD-844 suppresses tumor growth in mouse. VVD-844 can be used for the research of cancers .
    VVD-844

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: